FDA Alerts Public, Clinicians About Acetaminophen Recall
By News Staff
11/10/2006
FDA officials have issued a public alert about a nationwide recall of 383 lots of 500-milligram acetaminophen caplets following the discovery of small metal fragments in some of the caplets. The voluntary recall, which is being conducted by Perrigo Company of Allegan, Mich., involves approximately 11 million bottles manufactured and distributed under various store brand labels.
According to a Nov. 9 FDA news release, no instances of illness or injuries related to this problem and no consumer complaints have been reported to the FDA or to Perrigo.
Consumers can determine if they are in possession of a recalled bottle by locating the batch number printed on the container label. Visit the FDA Web site for a list of batches included in the recall and for a list of the stores that carry brands potentially involved in this action.
Although the likelihood of serious injury resulting from use of the affected acetaminophen is thought to be minimal, minor stomach discomfort or cuts to the mouth or throat could result from swallowing the pills. Consumers are encouraged to consult their physicians if they suspect they've been harmed by using this product.
Clinicians should report any adverse reactions to the FDA's MedWatch program via the MedWatch Web site, by phone at (800) FDA-1088 or by fax at (800) FDA-0178.
Consumers can determine if they are in possession of a recalled bottle by locating the batch number printed on the container label. Visit the FDA Web site for a list of batches included in the recall and for a list of the stores that carry brands potentially involved in this action.
Although the likelihood of serious injury resulting from use of the affected acetaminophen is thought to be minimal, minor stomach discomfort or cuts to the mouth or throat could result from swallowing the pills. Consumers are encouraged to consult their physicians if they suspect they've been harmed by using this product.
Clinicians should report any adverse reactions to the FDA's MedWatch program via the MedWatch Web site, by phone at (800) FDA-1088 or by fax at (800) FDA-0178.
Health of the Public
ER Visits on the Rise, Study Shows
Study: Small Prevention Steps Could Reap Big Gains
FDA Mandates Boxed Warning for Fluoroquinolones
New Ask and Act Podcasts Now Available
Tar Wars Celebrates 20th Anniversary
RWJ Initiative Aims to Create New Care Model
AIM Publishes Group Visits Guide
Study: Address Economic Burden of Chronic Disease
FDA Launches Proactive Drug Tracking System
AAFP/F, Diabetes Educators Team Up
New Network E-mails Product Safety Alerts








